e-Article
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation.
Document Type
Article
Author
Mastrangelo, Andrea; Monardo, Roberta; Galli, Laura; Tomelleri, Alessandro; Tassan Din, Chiara; Canetti, Diana; Messina, Emanuela; Guffanti, Monica; Danise, Anna; Campochiaro, Corrado; Cavalli, Giulio; Monti, Giacomo; Cinque, Paola; Scarpellini, Paolo; Landoni, Giovanni; Ciceri, Fabio; Dagna, Lorenzo; Castagna, Antonella; Ripa, Marco
Source
Subject
*COVID-19
*NONINVASIVE ventilation
*ANAKINRA
*CORTICOSTEROIDS
*PATIENT experience
*
*
*
*
Language
ISSN
0934-9723
Abstract
Management of COVID-19 patients experiencing persisting respiratory failure despite corticosteroids remains challenging. Data on high-dose intravenous anakinra (HD-ANK) in this context are lacking. We aimed to investigate the impact of HD-ANK on mortality in COVID-19 patients progressing to non-invasive ventilation (NIV) while receiving corticosteroids. We retrospectively analyzed the impact of HD-ANK on 28-day mortality in individuals hospitalized with COVID-19 necessitating NIV after corticosteroid initiation. A total of 256 patients were identified: 146 received standard-of-care only (SOC), and 110 received HD-ANK+SOC. The groups were well-balanced at baseline. In-hospital mortality at 28 days did not differ between the two groups. HD-ANK is not beneficial in patients with severe COVID-19 deteriorating despite corticosteroids. [ABSTRACT FROM AUTHOR]